Clinical trialPhase 1Withdrawn
JS001+IMP4297 in Patients With Advanced Cancer
A Phase Ⅰ/Ⅰb Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Toripalimab (Anti-PD-1 Antibody) in Combination With Senaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
- Outcome
- Stopped earlyThe sponsor voluntarily terminated the study before it was initiated (Business decision)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 29 March 2022
- Planned end
- 6 June 2024
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- DLT、AE、SAE、irAE; MTD; RP2D; ORR
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 21 September 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a Phase I/Ib open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of toripalimab in combination with senaparib in patients with advanced solid tumors. The study consists of 2 parts, the Phase I part of the study will be a dose-escalation evaluation to determine the RP2D of senaparib to be administered in combination with the fixed dose of toripalimab, and the Phase Ib portion will further evaluate the RP2D and evaluate the efficacy of combination in specific types of advanced solid tumors.